McGuire Investment Group LLC lowered its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating ) by 10.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 121,652 shares of the biopharmaceutical company’s stock after selling 14,651 shares during the quarter. Bristol-Myers Squibb accounts for approximately 1.6% of McGuire Investment Group LLC’s portfolio, making the stock its 23rd biggest holding. McGuire Investment Group LLC’s holdings in Bristol-Myers Squibb were worth $8,884,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the stock. Stratos Wealth Advisors LLC boosted its stake in Bristol-Myers Squibb by 10.4% in the 4th quarter. Stratos Wealth Advisors LLC now owns 41,528 shares of the biopharmaceutical company’s stock valued at $2,589,000 after purchasing an additional 3,929 shares in the last quarter. Fundamentun LLC boosted its stake in Bristol-Myers Squibb by 17.1% in the 4th quarter. Fundamentun LLC now owns 12,163 shares of the biopharmaceutical company’s stock valued at $758,000 after purchasing an additional 1,775 shares in the last quarter. BKD Wealth Advisors LLC boosted its stake in Bristol-Myers Squibb by 10.3% in the 4th quarter. BKD Wealth Advisors LLC now owns 11,663 shares of the biopharmaceutical company’s stock valued at $727,000 after buying an additional 1,089 shares during the last quarter. Wedmont Private Capital purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $422,000. Finally, Relyea Zuckerberg Hanson LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $324,000. 73, 07% of the shares are currently owned by hedge funds and other institutional investors.
BMY has been the subject of a number of research reports. Bank of America upped their target price on shares of Bristol-Myers Squibb from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 6th. Citigroup reaffirmed a “buy” rating and set a $90.00 target price on shares of Bristol-Myers Squibb in a report on Friday, June 3rd. Barclays upped their target price on shares of Bristol-Myers Squibb from $66.00 to $68.00 in a report on Monday, May 2nd. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $65.00 to $70.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 17th. Finally, Truist Financial boosted their price objective on shares of Bristol-Myers Squibb from $76.00 to $81.00 in a report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Moderate Buy” and an average price target of $74.27, according to MarketBeat.com.
In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of the business’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $74.04, for a total value of $2,221,200.00. Following the completion of the transaction, the chief executive officer now owns 551,104 shares in the company, valued at $40,803,740.16. The transaction was disclosed in a legal filing with the SEC, which is available via this hyperlink. Also, EVP Sandra Leung sold 65,000 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the completion of the transaction, the executive vice president now owns 308,627 shares of the company’s stock, valued at approximately $23,113,076.03. Disclosure of this sale can be found here. Insiders own 0.09% of the company’s stock.
Shares of Bristol-Myers Squibb stock opened at $75.96 on Wednesday. Bristol-Myers Squibb has a fifty-two week low of $53.22 and a fifty-two week high of $80.59. The company has a debt-to-equity ratio of 1.18, a quick earnings ratio of 1.23 and a current ratio of 1.32. The firm has a 50-day moving average of $76.13 and a 200-day moving average of $71.10. The company has a market cap of $161.72 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 1.63 and a beta of 0.45.
Bristol-Myers Squibb (NYSE:BMY – Get Rating ) last posted its earnings results on Friday, April 29. The biopharmaceutical company reported $1.96 earnings per share for the quarter, topping the consensus estimate of $1.92 by $0.04. The firm had revenue of $11.65 billion during the quarter, compared to the consensus estimate of $11.34 billion. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. In the same quarter last year, the firm earned $1.74 EPS. As a group, equities research analysts predict that Bristol-Myers Squibb will post 7.58 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be given a $0.54 dividend. The ex-dividend date of this dividend is Thursday, June 30th. This represents a $2.16 annual dividend and a dividend yield of 2.84%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 76.60%.
About Bristol-Myers Squibb (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunological, fibrotic, neurological and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor to reduce the risk of stroke/systemic embolism in NVAF and to treat DVT/PE; Opdivo for anticancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Want to see what other hedge funds hold BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating ).
Get news and ratings for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.